Piribedil is an antiparkinsonian agent and piperazine derivative which acts as a D 2 and D 3 receptor agonist. It also has α 2 -adrenergic antagonist properties. [2][3] The drug has been shown to enhance working memory capacities in normal aging adults. [4]

Piribedil is a piperazine derivative, a dopamine receptor agonist, which has been mainly used for the treatment of depression and Parkinson’s disease. It has also been recommended for the treatment of patients with intermittent claudication, without convincing evidence.

Piribedil is a dopamine agonist used with or without levodopa in the treatment of Parkinson's disease. Piribedil has been investigated in Parkinson's Disease. The next evolution of DrugBank is here. Designed for scientists, driven by AI, and powered by real-time insights. This is drug intelligence, redefined.

PIRIBEDIL is a small molecule drug with a maximum clinical trial phase of IV and is indicated for parkinson disease.

Piribedil is a direct dopamine agonist, in clinical use for treatment of dopaminergic system dysfunction. Recent work suggests that it is selective for the D3 subtype, for which it has 20 times higher affinity than for D2, and possesses no significant affinity for D1 receptors.

Piribedil acts as a non-ergot partial dopamine D2/D3-selective agonist, blocks alpha2-adrenoreceptors and has minimal effects on serotoninergic, cholinergic, and histaminergic receptors. Animal models support the efficacy of piribedil to improve parkinsonian motor symptoms with a lower propensity than levodopa to induce dyskinesia.

Piribedil is primarily prescribed for the treatment of Parkinson’s disease and other neurological conditions. It works by stimulating dopamine receptors in the brain, which helps improve motor function and reduce symptoms such as tremors.